1-5 of 5
Revathi Ananthakrishnan
Close
Sort by
Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 875–877.
https://doi.org/10.1182/blood-2022-162469
Published: 2022
Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel
Journal: Blood
Blood (2022) 140 (Supplement 1): 7441–7443.
https://doi.org/10.1182/blood-2022-162615
Published: 2022
Journal Articles

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

Anjali S. Advani, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Andrei R. Shustov, MD, Daniel J. DeAngelo, MD PhD, Revathi Ananthakrishnan, Katherine Liau, Erik Vandendries, MD, Wendy Stock, MD
Journal: Blood
Blood (2014) 124 (21): 2255.
https://doi.org/10.1182/blood.V124.21.2255.2255
Published: 2014
Journal Articles

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Daniel J. DeAngelo, MD, Ph.D, Wendy Stock, M.D., Andrei R. Shustov, MD, Michaela Liedtke, MD, Charles A. Schiffer, MD, Revathi Ananthakrishnan, Joseph P. Boni, PhD, Kenneth Luu, Katherine Liau, Erik Vandendries, MD, Anjali S. Advani, MD
Journal: Blood
Blood (2013) 122 (21): 3906.
https://doi.org/10.1182/blood.V122.21.3906.3906
Published: 2013
Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD
Journal: Blood
Blood (2013) 122 (21): 1821.
https://doi.org/10.1182/blood.V122.21.1821.1821
Published: 2013